Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 3:21 PM
Ignite Modification Date:
2025-12-24 @ 3:21 PM
NCT ID:
NCT05866692
Brief Summary:
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
Detailed Description:
To assess the safety and tolerability of TY-2699a when administered as a single agent in subjects with locally advanced or metastatic solid tumors.
To determine the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) as a single agent in subjects with locally advanced or metastatic solid tumors.
To evaluate the pharmacokinetics (PK) of TY-2699a administered at single and multiple oral doses.
To assess the preliminary antitumor activity of TY-2699a as a single agent in subjects with locally advanced or metastatic solid tumors.
Study:
NCT05866692
Study Brief:
Protocol Section:
NCT05866692